Bronte Capital Management Pty Ltd. 13F holdings, Q3 2020
Bronte Capital Management Pty Ltd. disclosed 12 US equity positions worth $517.4m in its Q3 2020 13F filing. Its largest position is BRK/B at 19.3% of the reported book, followed by HLF and GOOGL. Versus Q2 2020 it opened 4 new positions, added to 4, reduced 3 and exited 2.
- $517m
- Reported equity book Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
- 12
- Positions Distinct securities in the equity book with a reported value above zero. Options are excluded.
- 19.3%
- Largest position The largest single position as a share of the reported equity book.
- 98.9%
- Top 10 weight The ten largest positions together, as a share of the reported equity book.
- 7
- Effective positions 1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
- 31
- Quarters on file since Q4 2018 Quarters for which this manager's 13F holdings are on record.
Holdings
Against Q2 2020: 4 new, 4 added, 3 reduced, 2 exited
| BRK/B BERKSHIRE HATHAWAY INC DEL | 19.3% | +22% | added |
| HLF HERBALIFE LTD | 18.0% | −1.1% | reduced |
| GOOGL ALPHABET INC | 14.7% | +9.3% | added |
| V VISA INC | 14.0% | −2.1% | reduced |
| IBKR INTERACTIVE BROKERS GROUP IN | 12.0% | +5.2% | added |
| CTVA CORTEVA INC | 5.3% | −0.1% | held |
| NEM NEWMONT CORP | 4.6% | +16% | added |
| GOOG ALPHABET INC | 4.5% | −11% | reduced |
| BNY BANK OF NY MELLON CORP | 3.3% | – | new |
| STT STATE STR CORP | 3.1% | – | new |
| GHC GRAHAM HLDGS CO | 0.7% | – | new |
| MACKEUR MERRIMACK PHARMACEUTICALS IN | 0.4% | – | new |
Exited since Q2 2020
Sector mix
Book over time
Every quarter on file (31)
| Quarter | Positions | Equity book |
|---|---|---|
| Q2 2026 | 56 | $888m |
| Q1 2026 | 51 | $941m |
| Q4 2025 | 43 | $957m |
| Q3 2025 | 29 | $1.1bn |
| Q2 2025 | 27 | $1.3bn |
| Q1 2025 | 26 | $1.2bn |
| Q4 2024 | 24 | $1.3bn |
| Q3 2024 | 25 | $1.2bn |
| Q2 2024 | 28 | $1.3bn |
| Q1 2024 | 29 | $1.2bn |
| Q4 2023 | 29 | $1.1bn |
| Q3 2023 | 28 | $993m |
| Q2 2023 | 32 | $1.0bn |
| Q1 2023 | 30 | $862m |
| Q4 2022 | 27 | $793m |
| Q3 2022 | 28 | $803m |
| Q2 2022 | 30 | $829m |
| Q1 2022 | 28 | $709m |
| Q4 2021 | 24 | $770m |
| Q3 2021 | 23 | $694m |
| Q2 2021 | 17 | $666m |
| Q1 2021 | 14 | $571m |
| Q4 2020 | 13 | $517m |
| Q3 2020 | 12 | $517m |
| Q2 2020 | 10 | $446m |
| Q1 2020 | 11 | $377m |
| Q4 2019 | 7 | $344m |
| Q3 2019 | 10 | $336m |
| Q2 2019 | 9 | $263m |
| Q1 2019 | 11 | $266m |
| Q4 2018 | 9 | $239m |
Where Bronte Capital Management Pty Ltd. was early
Concentration and tenure
- 14.8%
- Median largest position, all quarters The largest single position as a share of the reported equity book.
- 79.8%
- Median top 10 weight, all quarters The ten largest positions together, as a share of the reported equity book.
- Concentrated
- Style, by median largest position
- 3
- Median completed holding, quarters